Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 39 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo (Fenofibrate) Clear all

Conditions: Non Familial Chylocmicronemia Syndrome (Non-FCS)
Interventions: LCQ908, Fenofibrate, Fish Oil, Placebo of LCQ908, Placebo of fenofibrate, Placebo of fish oil; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 28
States / cities: Muscle Shoals, Alabama • Glendale, Arizona • Encinitas, California + 23 more

Conditions: Second or Third Degree Burns
Interventions: Fenofibrate, Sugar Pill; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 4 Years to 20 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 18
States / cities: Sacramento, California • Golden, Colorado • Miami, Florida + 13 more

Conditions: Hyperlipidemias
Interventions: Lapaquistat acetate and fenofibrate, Fenofibrate; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 32
States / cities: Huntsville, Alabama • Sierra Vista, Arizona • Beverly Hills, California + 29 more

Conditions: Fatty Liver
Interventions: fenofibrate, pioglitazone, placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetic Nephropathies
Interventions: Fenofibrate, Placebo; Drug · Other
Lead sponsor: Alessandro Doria; Other
Eligibility: 18 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Boston, Massachusetts • Burlington, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Hypercholesterolemia
Interventions: Alirocumab, Placebo (for Alirocumab), Non-statin LMT, Diet Alone; Drug · Other
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Atlantis, Florida • Jacksonville, Florida + 5 more

Conditions: Coronary Atherosclerosis
Interventions: Placebo, TriLipix; Drug
Lead sponsor: Piedmont Healthcare; Other
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Dyslipidaemias
Interventions: GW590735, fenofibrate; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 45
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 38 more

Conditions: Type II Diabetes Mellitus, Diabetes Complications
Interventions: Fenofibrate, Placebo for fenofibrate; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 30 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Niacin, fenofibrate, placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Metabolic Syndrome x
Interventions: Study drugs: Metformin and fenofibrate, Study Drug: Metformin, Study Drug: fenofibrate, Metformin and Fenofibrate placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 124 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypercholesterolemia, Hyperlipidemia, Familial Combined
Interventions: colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 30 Years to 70 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Longwood, Florida • Ocala, Florida • Winterpark, Florida + 7 more

Conditions: Severe Hypertriglyceridemia
Interventions: K-877, Fenofibrate, Placebo (for K-877); Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 129
States / cities: Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more

Conditions: Diabetic Retinopathy
Interventions: Fenofibrate, Placebo; Drug · Other
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years to 80 Years
Enrollment: 563 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 66
States / cities: Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more

Search by objective public record fields.

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

Acute and Long-Term Outcome Investigations of Fenofibrate on Severely Burned Patients

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels

Insulin Resistance in Non-alcoholic Fatty Liver Disease

A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes

Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

AFRICA: Atorvastatin Plus Fenofibric Acid (TriLipix) in the Reduction of Intermediate Coronary Atherosclerosis

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Lipid Biomarkers for Diabetic Heart Disease

Obesity and Nonalcoholic Fatty Liver Disease

The Fenofibrate and Metformin for Atherogenic Dyslipidemia (FAMA) Study

Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

Fenofibrate for Prevention of DR Worsening